We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

11 hedge funds and large institutions have $422K invested in CNS Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

664% more capital invested

Capital invested by funds: $55.2K → $422K (+$367K)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

57% more funds holding

Funds holding: 7 → 11 (+4)

0.67% more ownership

Funds ownership: 0.12% → 0.78% (+0.67%)

Holders
11
Holders Change
+4
Holders Change %
+57.14%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$423K
2
VF
Virtu Financial
New York
+$24.4K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$18.6K
4
TSS
Two Sigma Securities
New York
+$16.3K
5
HF
HRT Financial
New York
+$11.3K

Top Sellers

Rank Fund Capital Flow
1
GSC
Ground Swell Capital
South Carolina
-$15.4K

CNSP Hedge Fund Activity: Q2 2025 in Review

11 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q2 2025, worth a combined $422K — up 664% from $55.2K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CNSP positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $423K. The largest seller was Ground Swell Capital, exiting entirely with an estimated $15.4K sold.

  • 11 institutional investors held CNS Pharmaceuticals (CNSP) as of Q2 2025, up from 7 in Q1 2025.
  • Funds reported $422K of CNS Pharmaceuticals stock for Q2 2025, up 664% quarter-over-quarter.
  • 5 funds opened new CNS Pharmaceuticals positions in Q2 2025 and 1 closed out, a net change of +4 holders.
  • The largest CNS Pharmaceuticals buyer in Q2 2025 was Armistice Capital, an estimated $423K added.
  • The largest CNS Pharmaceuticals seller in Q2 2025 was Ground Swell Capital, an estimated $15.4K sold.

Based on aggregated 13F filings for Q2 2025.